Several late-phase results were shared during the European Society of Medical Oncology (ESMO) Virtual Congress in gynecologic malignancies, but the data presented generated excitement about the number of novel options for patients after initial treatment.
Updated findings in ovarian cancer demonstrated continued benefit for PARP inhibition as maintenance therapies following frontline treatment in advanced ovarian cancer in the phase 3 SOLO-1 trial (NCT01844986) using the PARP inhibitor olaparib (Lynparza) and in the phase 2 PRIMA/ENGOT-OV26/GOG-3012 ([PRIMA], NCT02655016), which utilized the PARP inhibitor niraparib (Zejula).
Enthusiasm also surrounded a potential new approach in cervical cancer from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study ([innovaTV], NCT03438396), which explored treatment with the investigational antibody-drug conjugate tisotumab vedotin.
The longest duration of follow-up for any PARP inhibitor in the previously untreated advanced ovarian cancer setting was performed in the phase 3, randomized, double-blind, placebo-controlled, multicenter SOLO-1 trial, in which olaparib maintenance was given to patients with BRCA mutations. The 5-year follow-up results were presented at ESMO by Susan Banerjee, MD, PhD, FRCP, consultant medical oncologist and research lead for the Gynecology Unit at The Royal Marsden.1
The updated analysis after 5 years of follow-up shows that the benefit of olaparib continues substantially beyond the end of treatment, Banerjee told Targeted Oncology in an interview.
Out of the 391 patients assessed, 260 received olaparib maintenance and 131 received placebo for up to 2 years or until progressive disease (PD). Olaparib maintenance first demonstrated an improvement in progression-free survival (PFS) in the primary analysis with the median PFS not yet reached in the olaparib arm at this timepoint compared with 13.8 months in the placebo arm (HR, 0.30; 95% CI, 0.23-0.41).
The median follow-up for the updated analysis was 4.8 years in the olaparib arm compared with 5.0 years in the placebo arm. The results showed PFS events in 45% of the olaparib-treated population versus 76% of the placebo population. The median PFS observed with olaparib maintenance was 56.0 months compared with 13.8 months in the placebo arm (HR, 0.33; 95% CI, 0.25-0.43).
These are very encouraging results that will help us explain the potential benefits of maintenance olaparib in patients with BRCA mutations, said Banerjee.
A new analysis of the phase 3 randomized, double-blind, placebo-controlled, multicenter PRIMA trial presented during ESMO by GiorgioValabrega, MD, investigated the potential difference in efficacy and safety by age of niraparib maintenance after chemotherapy in patients with advanced ovarian cancer.
The key findings of our trial were that there is no difference in terms of safety and efficacy by adding niraparib to chemotherapy. Also, the [adverse events] that were observed in patients above 65 and 75 [years of age] in comparison to younger patients are not different, Valabrega, associate professor, University of Torino School of Medicine, told Targeted Oncology in an interview.
The subanalysis included 444 patients from the original PRIMA study who were 65 years of age or younger. Of the patients included in this analysis, 297 received niraparib and 147 received placebo.2
A second cohort from the analysis included 289 patients aged 65 or older. Among this group, 76 patients were 75 years or older. One hundred ninety of the patients received niraparib maintenance while 99 received placebo in the younger cohort and of those 75 years or older, 54 patients received niraparib and 22 received placebo.
Demonstrating consistency with the primary analysis which showed a median PFS on 13.8 months with niraparib compared with 8.2 months in the placebo arm, niraparib maintenance prolonged PFS compared with placebo in this subanalysis. In the patients under the age of 65, the median PFS was 13.9 months with niraparib versus 8.2 months with placebo (HR, 0.61; 95% CI, 0.47-0.81). Patients aged 65 or older had a median PFS of 13.7 months with niraparib versus 8.1 months with placebo (HR, 0.53; 95% CI, 0.39-0.74). In the 75 years of age or below group, niraparib led to a median PFS of 13.8 months compared with placebo, which had a median PFS of 8.2 months (HR, 0.62; 95% CI, 0.50-0.77). Finally, in patients aged 75 of older, the median PFS was 13.8 months with niraparib versus 5.6 months with placebo (HR, 0.37; 95% CI, 0.17-0.81).
Both ages groups were similar in terms of the number percentage of treatment-emergent adverse events (TEAEs) observed. The most common treatment-emergent TEAEs were anemia, leukopenia and hypertension. Notably, patients aged 65 years or older experienced a small increase in thrombocytopenia during treatment as did those aged 75 years of age or older. The rates of 3 TEAEs were also similar between the age groups.
Results from the single-arm, multicenter, international phase 2 study innovaTV were presented during ESMO by Robert Coleman, MD, FACOG, FACS, chief scientific officer of The US Oncology Network. The result of the study was that treatment with tisotumab vedotin led to antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.3
We basically confirmed the responses that we saw in the first-in-human phase 1 and 2 study with a 24% response rate, Coleman told Targeted Oncology.
Importantly, 7% of those patients had complete response, which, for those of who have treated this disease, these are not common findings, he added.
As Coleman shared, the objective response rate observed in the trial was 24% (95% CI, 15.9%-33.3%), with complete responses in 7% of the population, partial respondes in 17%, and stable disease in 49%. In terms of PD, 24% of patients progressed on treatment. The median duration of response observed with tisotumab vedotin was 8.3 months (95% CI, 4.2 to not reached). Notably, the treatment also led to a decrease in target lesion size in 79% of the patients who received tisotumab vedotin when compared with their baseline measurements.
Among the confirmed responders, the median time to response was 1.4 months (range, 1.1-5.1). It was also noted during Colemans ESMO presentation that responses were seen across the subgroup populations explored, regardless of tumor histology, lines of prior therapy, or responses to prior treatment.
The median PFS achieved with tisotumab vedotin was 4.2 months (95% CI, 3.0-4.4). At 6 months, the PFS rate was 30% (95% CI, 20.8%-40.1%). The median overall survival with the agent was 12.1 months (95% CI, 9.6-13.9) and the 6-month OS rate was 79% (95% CI, 69.3%-85.6%).
Treatment-related AEs (TRAEs) occurred in greater than 10% of the study population. The majority of the (TRAEs) observed in this study were grade 1 and 2 in severity. The most TRAEs of any grade were alopecia (38%), epistaxis (30%), nausea (27%), conjunctivitis (26%), and fatigue (24%). One patient in the died as a results of treatment-related septic shock.
Ocular, bleeding, and neuropathy TRAEs were also assessed in the study and bleeding TRAES were most prevalent, with grade 1 events having observed in 34% of patients. Ocular TRAEs were the second most prevalent with grade 1 events having occurred in 25% of patients. Finally, grade 1 peripheral neuropathy occurred in 17% of patients.
Data from this study led to the conclusion that tisotumab vedotin is a potential new treatment option for patients with previously treated recurrent of metastatic cervical cancer.
References:
1. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020. Virtual. Abstract 811M0.
2. Valabrega G, Pothuri B, Oaknin A, et al. Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract 819P.
3. Coleman RL, Larusso D, Gennigens C, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study. Presented at: 2020 ESMO Virtual Congress; September 19-21, 2020; Virtual. Abstract LBA32.
Original post:
Updated Findings Show Continued Benefit of PARP in Ovarian Cancer, New Agent on the Scene in Cervical Cancer - Targeted Oncology
- 001 Guidelines for Veterans Agent Orange and Peripheral ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 002 CBD and Neuropathy: Almost Magical Pain Relief Benefits [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 003 Peripheral neuropathy - Wikipedia [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 004 Peripheral neuropathy - Symptoms and causes - Mayo Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 005 What is Neuropathy? | Neuropathy Support Network [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 006 What Is Peripheral Neuropathy? | Living With Peripheral ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 007 Neuropathy, Cancer, Information, Resources | CancerCare [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 008 Neuropathy | Cleveland Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 009 List of Peripheral Neuropathy Medications (11 Compared ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 010 Neuropathy - Lab Tests Online [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 011 10 Symptoms of Neuropathy - Bodily Numbness and Tingling [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 012 Peripheral neuropathy - Diagnosis and treatment - Mayo Clinic [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 013 Neuropathy: Symptoms, Causes, Types, Treatment, Nutrition ... [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 014 Neuropathy Types (Diabetic), Causes, Treatment, & Medication [Last Updated On: October 1st, 2018] [Originally Added On: October 1st, 2018]
- 015 Peripheral Neuropathy | Johns Hopkins Medicine Health Library [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 016 NJ Neuropathy Treatment & Surgery - Discover Your Options! [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 017 Drugs Causing Peripheral Neuropathy - Medications List [Last Updated On: October 18th, 2018] [Originally Added On: October 18th, 2018]
- 018 What Is Neuropathic Pain? Treatment, Medication, Definition [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 019 Nerve Remedy Reviews [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 020 Neuropathy - breastcancer.org [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 021 Diabetic neuropathy - Wikipedia [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 022 11 Symptoms and Treatments for Neuropathy | Daily Natural ... [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 023 Neuropathy | LIVESTRONG [Last Updated On: November 1st, 2018] [Originally Added On: November 1st, 2018]
- 024 What Is Diabetic Neuropathy? | NIDDK [Last Updated On: January 6th, 2019] [Originally Added On: January 6th, 2019]
- 025 Polyneuropathy - Wikipedia [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 026 Peripheral neuropathy - Illnesses & conditions | NHS inform [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 027 Peripheral Neuropathy | NIDDK [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 028 Peripheral Neuropathy | Johns Hopkins Medicine [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 029 Peripheral Neuropathy Symptoms | Pain In Fingers, Toes, & Feet. [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 030 The Best Treatment for Peripheral Neuropathy in Feet ... [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 031 10 Causes of Neuropathy - Facty Health [Last Updated On: October 3rd, 2019] [Originally Added On: October 3rd, 2019]
- 032 There's a Depressing Difference Between The Sewage of Wealthy Areas And Poorer Ones - ScienceAlert [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 033 Stealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma - Seeking Alpha [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 034 Peripheral Neuropathy Treatment Market 2025: Topmost manufacturers With Size, Regions, Types, Major Drivers, Profits - TheFinanceTime [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 035 Connecting smartphones to depression | News - Inside Tucson Business [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 036 Global Cardiac Autonomic Neuropathy Treatment Market Top Insights 2020:-Novartis, Pfizer and Roche Holding - Tech News Today [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 037 Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears - AJMC.com Managed Markets Network [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 038 Does Aspirin Protect Against Nonarteritic Ischemic Optic Neuropathy Development in Men? - Monthly Prescribing Reference [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 039 No Link Between Nutritional Deficiencies, Vincristine-Induced Neuropathy in Pediatric Acute Lymphoblastic Leukemia - Cancer Therapy Advisor [Last Updated On: October 13th, 2019] [Originally Added On: October 13th, 2019]
- 040 California Medical Evaluators Grows its Network of Pain Medicine Experts in the San Francisco Bay Area - Business Wire [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 041 How Caregivers and Patients Can Manage Bodily Responses to Stress - FAP News Today [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 042 Diabetic Neuropathy Drugs Market 2019-2023 | Evolving Opportunities with Pfizer Inc. and Novartis AG | Technavio - Business Wire [Last Updated On: October 17th, 2019] [Originally Added On: October 17th, 2019]
- 043 Surviving breast cancer what comes next? - Hudson Valley 360 [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 044 PDF Report : Diabetic Neuropathy Market 2019 || Comprehensive Analysis of the market with Competitive Landscape and Forecasts To 2028 - Tech News... [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 045 Advanced Nerve & Health Center helps breast cancer survivor reverse her neuropathy - KHOU.com [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 046 Cardiac Autonomic Neuropathy Treatment Market expected to Witness a Sustainable Growth over 2017 2025 - Health News Office [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 047 UI-led neuropathy consortium receives grant renewal from National Institute of Health - UI The Daily Iowan [Last Updated On: October 25th, 2019] [Originally Added On: October 25th, 2019]
- 048 Addressing Cardiovascular Risk Factors in People with Diabetes - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 049 Diabetic Peripheral Neuropathy Market - Growth, Future Prospects, and Competitive Analysis 2028 - Market Tribunal [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 050 Chemotherapy Induced Peripheral Neuropathy Treatment Market to Generate Higher Revenues by Entering into Strategic Collaborations says Fortune... [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 051 Global Neuropathy Pain Treatment Profiling Industry 2019 Market Share, Regional Analysis, Growth Insights, Leading Companies, End Users and Forecast... [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 052 Neuropathy Pain Treatment Market Set For Rapid Growth and Trend | Statistics Analysis and Opportunities 2024 - News Description [Last Updated On: November 12th, 2019] [Originally Added On: November 12th, 2019]
- 053 Phase 3 Trial of Investigative FAP Therapy AKCEA-TTR-LRx Launching - FAP News Today [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 054 Study to search for early signs of peripheral neuropathy in people with diabetes - Griffith News [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 055 Cardiac Autonomic Neuropathy Treatment Market by Size | Growth | Analysis | Trends and Forecasts to 2017 2025 - chronicles24 [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 056 Diabetic Neuropathy Market: Technological Growth Map over Time to Understand the Industry Growth Rate - Montana Ledger [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 057 Potential Link Between Tumor Necrosis Factor- and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma - Oncology Nurse... [Last Updated On: November 29th, 2019] [Originally Added On: November 29th, 2019]
- 058 Pain under left armpit: Causes and what to do - Medical News Today [Last Updated On: November 30th, 2019] [Originally Added On: November 30th, 2019]
- 059 ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 060 Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 061 Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - World Industry Reports [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 062 Health watch: 5 things to know about chemotherapy - StarNewsOnline.com [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 063 Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 064 Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 - 2029 - Markets Gazette... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 065 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 066 Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic... [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 067 Looney gives up two aspects of diet to combat neuropathy - NBCSports.com [Last Updated On: December 15th, 2019] [Originally Added On: December 15th, 2019]
- 068 What You Need to Know About the FDA - Curetoday.com [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 069 3 Affordable Herbs & Vitamins that you should try for nerve pain relief - Explosion [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 070 Diabetic Neuropathy Market Poised to Take Off by 2026 - Market Research Sheets [Last Updated On: December 30th, 2019] [Originally Added On: December 30th, 2019]
- 071 Leber's Hereditary Optic Neuropathy, 2019 - Pipeline Review, H2 - ResearchAndMarkets.com - Business Wire [Last Updated On: January 3rd, 2020] [Originally Added On: January 3rd, 2020]
- 072 Diabetic Neuropathy Market Innovations, And Top Companies Forecast To 2029| Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc - Neptune Pine [Last Updated On: January 3rd, 2020] [Originally Added On: January 3rd, 2020]
- 073 The health benefits of lemon water | News - WPSD Local 6 [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 074 NeuroMetrix Reports Q4 and Full Year 2019 Financial Results - BioSpace [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 075 Fighting the Fire: Battling Rare Neuropathy, San Juan Hills' Efstathiou Coaches with New Perspective - Capistrano Dispatch [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 076 Peripheral Neuropathy Symptoms, Causes, Treatment & Prognosis [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 077 A 40-Year-Old Man With Dizziness, Confusion, and Neuropathy - Medscape [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 078 Neuropathy Signs, Symptoms, and Diagnosis | Everyday Health [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 079 Peripheral Neuropathy Fact Sheet | National Institute of ... [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]
- 080 Peripheral Neuropathy: Causes, Symptoms and Treatments [Last Updated On: January 28th, 2020] [Originally Added On: January 28th, 2020]